The federal government’s proposed Agile Licensing drug approval regulations mean Canada will have less information about the risks of new medicines, and higher costs.
Articles on Drug costs
Displaying all articles
New payment models may mean more of the people who need these treatments can get them.
FDA approval of aducanumab (Aduhelm) was contentious. Its submission to Health Canada for approval highlights concerns about evidence, independence and transparency in Canada’s drug approval process.
Studies repeatedly have shown that health care in general and the high cost of drugs in particular are among the top concerns of US voters. But with coronavirus, the issue may fade from prominence.
It’s not the price of health care that should concern us. It’s the cost. There’s a distinction, and it matters. Here’s why.
Support for over-the-counter birth control pills is growing. But a drawback could be that insurers would not pay for them. Also, some people have safety concerns. Could pharmacists be the solution?
CVS, which operates nearly 10,000 pharmacies across the country, announced intentions to buy Aetna, the nation’s third-largest provider of health insurance. Here’s how consumers could be affected.
Have you ever wondered why some drugs are so cheap, and others so expensive? Here’s why.
Top contributors
-
Senior Research Fellow, University of Technology Sydney
-
Professor of Health Law and Bioethics, Case Western Reserve University
-
PhD Candidate in Health Economics, University of Technology Sydney
-
Professor of Health Economics, University of Technology Sydney
-
Associate Professor of Public Health, The Ohio State University
-
Clinical Associate Professor of Pharmacy Practice, Binghamton University, State University of New York
-
Associate professor, Department of Family and Community Medicine, University of Toronto; York University, Canada; University of Sydney
-
Associate Professor, School of Public Health, University of Alberta
-
Professor, School of Population and Public Health, University of British Columbia
-
Director of the Health Justice Institute at the Schulich School of Law, Dalhousie University
-
Postdoctoral Fellow in Precision Medicine and Emerging Biotechnologies, Arizona State University
-
Associate Professor of Surgery and Public Policy, University of Virginia
-
Professor of Economics, University of Calgary
-
Christopher McCabe is a Friend of The Conversation.
Professor of Health Economics, Queen's University Belfast